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Background: The mechanism underlying the coexistence of hepatitis B surface antigen and
antibodies to HBsAg in chronic hepatitis B patients remains unknown.
Aims: This research aimed to determine the clinical and virological features of the rare
pattern.
Methods: A total of 32 chronic hepatitis B patients infected by HBV genotype C were included:
15  carrying both HBsAg and anti-HBs (group I) and 17 solely positive for HBsAg (group II). S
gene  and reverse transcriptase region sequences were ampliﬁed, sequenced and compared
with  the reference sequences.
Results: The amino acid variability within major hydrophilic region, especially the “a”
determinant region, and within reverse transcriptase for regions overlapping the major
hydrophilic region in group I is signiﬁcantly higher than those in group II. Mutation sI126S/T
within the “a” determinant was the most frequent change, and only patients from group
I  had the sQ129R, sG130N, sF134I, sG145R amino acid changes, which are known to alter
immunogenicity.
Conclusions: In chronic patients, the concurrent HBsAg/anti-HBs serological proﬁle is asso-
ciated with an increased aa variability in several key areas of HBV genome. Additionalresearch on these genetic mutants are needed to clarify their biological signiﬁcance for
viral persistence.
© 2015 Elsevier Editora Ltda. All rights reserved.∗ Corresponding author.
E-mail address: yuhonggang@yahoo.com (H.-G. Yu).
ttp://dx.doi.org/10.1016/j.bjid.2015.08.014
413-8670/© 2015 Elsevier Editora Ltda. All rights reserved.
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Introduction
Hepatitis B virus (HBV) infection is a serious global public
health problem, and its prevalence varies considerably from
region to region. Worldwide, more  than 350 million people
are chronic carriers of HBV, and have a risk of dying from
development of cirrhosis and hepatocellular carcinoma.1 Clin-
ically, the appearance of circulating hepatitis B surface antigen
(HBsAg) heralds HBV infection, whereas the presence of the
antibody to HBsAg (anti-HBs) usually indicates resolution of
infection and is considered indicative of immunity to HBV
infection.2 It is generally believed that anti-HBs can neutral-
ize and clear HBsAg. Therefore, the concomitant presence in
the same serum of HBsAg and anti-HBs could be possible.
However, the persistence of HBsAg associated with anti-HBs
in patients with chronic HBV infection has been reported in
previous studies.3–5 So far, the mechanism underlying the
concurrent detection of HBsAg and anti-HBs remains largely
controversial.
HBV genome contains four partially overlapping open read-
ing frames (ORF), and the “a” determinant is located at codon
positions 124–147 within the major hydrophilic region (MHR)
of the HBsAg. This determinant is the main target of recogni-
tion of HBsAg by anti-HBs and immune response cells during
the course of the initial immune response in acute hepatitis
B. HBV has been classiﬁed into eight genotypes, designated
as A–H, and the most prevalent genotypes in China are geno-
types B and C.5 Notably, previous reports documented that, in
comparison to genotype B, genotype C takes a more  aggres-
sive disease course and has a lower response rate to antiviral
therapy.6–9
Several reports showed the paradoxical coexistence of
HBsAg and anti-HBs might be associated with the selection
of HBV immune escape mutants during chronic carriage.10–12
These studies documented increased amino acid (aa) muta-
tions in and around the “a” determinant, which is responsible
for the stability and immunogenicity of HBsAg.13 Nonetheless,
a later report rejected this hypothesis and instead suggested
that the pattern of simultaneous appearance of HBsAg and
anti-HBs was related to the weak binding of anti-HBs to
HBsAg.12 As the reverse transcriptase (RT) region of HBV poly-
merase gene overlaps the HBsAg ORF, mutations within HBsAg
gene might result in structural and functional alterations in
the HBV reverse transcriptase with potential inﬂuence on viral
replication capacity and efﬁcacy of antiviral drugs.14,15
Therefore, the aims of this study were to investigate the
prevalence of the coexistence of anti-HBs in HBsAg-positive
CHB patients infected with genotype C HBV, and explore the
relationship between the variability of the HBV S gene and the
paradoxical serological proﬁle.
Materials  and  methods
PatientsFrom January to December 2013, 1194 patients with CHB
recruited from Wuhan, Huangshi, and Yichang were enrolled
in the study. The inclusion criteria were HBsAg carriage 2 0 1 6;2  0(1):1–7
for more  than six months, HBV DNA concentration of
>1 × 104 IU/mL, serum alanine aminotransferase (ALT) >2 ULN
(upper limit of normal), and associated symptoms. Exclusion
criteria included having received passive immunization, previ-
ous antiviral therapy, coinfection with other hepatitis viruses,
or HIV. Sera were collected and stored at −70 ◦C. All individuals
provided written informed consent before entering the study.
Serologic  testing
HBV serological markers were determined by using the chemi-
luminescent microparticle immunoassay (CMIA) technique
with an Architect-i2000 automatic analyzer (Abbott Labo-
ratories, USA). Commercially available kits were purchased
from Abbott Laboratories. The analytical threshold of anti-HBs
was deﬁned as 10 mIU/mL. Serum was diluted according to
the Manual Dilution Procedure if HBsAg concentration value
>250,00 IU/mL. ALT was assayed with an ADVIA automatic bio-
chemical analyzer (Siemens, Germany).
HBV  DNA  quantiﬁcation
HBV DNA was quantiﬁed in serum using a commercially avail-
able real time ﬂuorescence quantitative kit (Da An, China) with
a lower detection threshold of 500 copies/mL.
Serum  DNA  extraction
Viral DNA was extracted from 200 L of serum using QIAamp
DNA blood mini kit (Qiagen, Germany) according to the man-
ufacturer’s instructions.
PCR  ampliﬁcation  and  sequencing  of  PCR  fragment
Ampliﬁcation and sequencing of the full-length S gene and
the overlapping RT regions were performed using the protocol
as follows. The primer sequences were synthesized by Bei-
jing SBS Biotechnology Company. PCR was carried out in a
50-L reaction mixture containing 10 L of HBV DNA template,
0.2 M each primer, 0.2 mM of each dNTP, 2 mM MgCl2, and
1 L of high-ﬁdelity Taq polymerase (Takara, China). Besides,
PCR was performed with hot start and denaturation at 94 ◦C
for 5 min, 35 cycles at 94 ◦C for 1 min, at 50 ◦C for 1 min,
and at 72 ◦C for 2 min, then incubated at 72 ◦C for 5 min. In
order to obtain a complete description of HBV quasispecies,
sequence analysis was performed with the powerful ultra-
deep sequencing (UDS) approach, using the primers according
to the reference sequence X04615 (the upstream primer: 5′-
GTCACCATATTCTTGGGAAC-3′ nt2818-2837; the downstream
primer: 5′-CATATCCCATGAAGTTAAGG-3′ nt 888–869).12
Sequence  analysis
Genomic sequences obtained for the S gene and the over-
lapping RT regions were translated into aa sequences and
compared with HBV reference sequences used on the NCBI
Website (http://www.ncbi.nih.gov/projects/genotyping/view.
cgi?db=2). For analysis, the full-length S protein was divided
into three regions corresponding to structural and/or func-
tional domains: the N terminal region (aa 1–99), the MHR
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Table 1 – Summary of clinical features of patients with concurrent HBsAg and anti-HBs.
Patient Gender/age HBsAg (IU/mL) Anti-HBs (mIU/mL) ALT (IU/L) HBeAg HBV-DNA
P1 F/23 325.6 1326.5 224 Pos 8.63E+07
P2 M/40 103.19 51.21 95 Neg 5.35E+05
P3 M/27 102.28 156.8 168 Pos 5.36E+06
P4 F/21 179.88 36.9 147 Pos 5.20E+06
P5 M/30 167.17 23.6 103 Neg 2.36E+04
P6 M/29 122.47 111.25 115 Pos 3.12E+06
P7 F/31 85.72 62.36 98 Pos 6.45E+06
P8 F/22 669.81 20.65 214 Pos 2.80E+08
P9 M/29 92.28 18.52 136 Pos 6.35E+06
P10 M/31 116.6 26.32 94 Neg 3.68E+05
P11 F/25 522.53 19.62 197 Pos 5.61E+07
P12 M/35 93.18 85.26 115 Pos 3.26E+05
P13 M/28 72.01 35.15 94 Pos 3.72E+04
P14 F/31 126.07 25.36 97 Neg 4.35E+05
P15 F/33 718.63 120.56 319 Pos 3.16E+09
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vM, male; F, female; Pos, positive; Neg, negative; ALT, alanine aminotra
aa 100–169), which contains the “a” determinant (aa 124–147),
nd the C terminal region (aa 170–226).
tatistical  analysis
ata were stored using Microsoft Excel and analyzed using
PSS 17.0 software (Chicago, IL). Quantitative data were com-
ared using Mann–Whitney or t test, and mutation rates were
nalyzed with the Chi-square test. Statistical signiﬁcance was
etermined at a p-value <0.05.
esults
haracteristics  of  patients
ut of the 1194 CHB patients enrolled in this study, in 36 (3.0%)
BsAg and anti-HBs were concomitantly detected. In order to
lucidate the mechanisms of coexistence of HBsAg and anti-
Bs in patients infected with HBV of the genotype C, two
roups were set up on the basis of their serological proﬁle.
Fifteen HBsAg+/anti-HBs+ CHB patients infected with
enotype C HBV were enrolled as the experimental group
group I). Meanwhile, 17 HBsAg+/anti-HBs− CHB patients
nfected with genotype C HBV were selected as the control
roup (group II). None of the patients had neither received
accination against HBV nor antiviral therapy.
Table 2 – Comparative analysis of clinical features of patients b
Gro
(n =
Age, median years (range) 29 (21–40)
Gender, female:male 7:8 
HBsAg titer, median IU/mL (range) 122.47 (72
HBeAg+ (%) 73.3 
Serum ALT level, median IU/L (range) 115 (94–31
Serum HBV DNA level, median (log 10 copies/mL) 6.71 (4.37
ALT, alanine aminotransferase.rase.
Table 1 shows the clinical characteristics of group I. There
were no signiﬁcant differences between group I and group
II with regard to age, gender, serum ALT level, HBsAg level,
HBeAg positivity rate, HBV DNA concentration (p = 0.127, 0.755,
0.692, 0.610, 0.388, 0.234, respectively) (Table 2). Importantly,
the patients with anti-HBs had rather higher anti-HBs level,
with a median titer of 36.9 mIU/mL (range, 18.52–1326.5).
Sequencing  of  S  gene  in  HBV
The entire S encoding gene sequences for patients with
and without anti-HBs were available by PCR ampliﬁcation
and sequencing, and subsequently compared to reference
sequences of the same genotype (Figs. 1 and 2 and Table 3).
Thirteen patients from group I had single or multiple aa
substitutions within the S protein.
The distributions of aa substitutions were heterogeneous
along the S protein (Fig. 2). Apparently, the highest frequency
of aa substitutions was observed within the “a” determinant
for both groups. Besides, aa variability within the MHR  was
markedly higher than that in the N-terminal region and the
C-terminal region.
Furthermore, when considering the full-length S coding
region, a marked aa substitution difference was observed
between group I and group II (1.45 vs. 0.55, for substitutions
per 100 aa, the same below, p = 0.000) (Table 3). Moreover, the
percentage of aa substitutions in the MHR  for group I was
etween group I and group II.
up I
 15)
Group  II
(n = 17)
p
 30 (18–43) 0.127
7:10 0.755
.01–718.63) 119.37 (68.25–625.53) 0.610
58.8 0.388
9) 147 (92–325) 0.692
–9.50) 5.57 (4.42–8.71) 0.234
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Fig. 1 – Amino acid substitutions within HBsAg and the overlapping regions of reverse transcriptase from patients with
concurrent HBsAg and anti-HBs. The part within the “a” determinant is underlined. Reference sequences of genotype C are
obtained from the NCBI website (http://www.ncbi.nlm.nih.gov/projects/genotyping/genotype C: X046151). A short line
 reprdemonstrates there is no mutation in this locus, and “stop”
signiﬁcantly higher compared to those of group II (2.67 vs. 0.67,
p = 0.000) (Table 3). Those substitutions were strikingly found
in the “a” determinant (4.12 vs. 1.47, p = 0.022) (Table 3). Inter-
estingly, great differences were also found in the N-terminal
region between the two groups (1.01 vs. 0.42, p = 0.044). These
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Fig. 2 – Frequencies of residue substitutions within HBsAg of HB
(gray bars) or without (group II) (black bars) simultaneous anti-Hesents the stop codon.
results indicate that the coexistence of HBsAg and anti-HBs is
related to the accumulation of mutated residues, mostly, but
not only, within the “a” determinant.
Mutation sI126S/T within the “a” determinant was the most
frequent change, being present in 40% of HBV sequences from
-determinant
 hydrophilic region C-Terminal region
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Table 3 – Number of substitutions per 100 amino acid positions within HBsAg and overlapping regions of reverse
transcriptase.
Region of HBsAg HBsAg HBsAg overlapping regions of reverse transcriptase
Group I Group II p Group I Group II p
Complete HBsAg 1.45 0.55 0.000
Complete RT 0.71 0.26 0.005
N-terminal Region 1.01 0.42 0.044 0.34 0.18 0.595
MHR 2.67 0.67 0.000 1.14 0.17 0.003
0.022 
0.828 
g
a
s
i
p
g
H
A
g
c
b
n
o
l
g
g
o
d
g
t
s
o
s
F
s
p
D
T
a
t
i
R
d
i
t
b
s
t
C
i
p
Ca-Determinant 4.12 1.47 
C-terminal Region 0.70 0.62 
roup I compared to 18% of HBV sequences from group II. In
ddition, only patients from group I had aa changes sQ129R,
G130N, sF134I, and sG145R, which have been proven to alter
mmunogenicity.4,16 However, substitution sG145R, which was
opular in previous study, was only found in one patient from
roup I.
BV  reverse  transcriptase  sequences
s the RT regions overlap the S gene, mutations within S
ene might lead to aa substitutions in RT regions. Theoreti-
ally, the highest aa variability regions within the RT should
e those overlapping the MHR, and especially the “a” determi-
ant located in a structural and functional “ﬁnger” subdomain
f the enzyme (Table 3).17 It was natural that the RT over-
apping region the MHR, the number of aa substitutions of
roup I patients was markedly increased compared to those of
roup II patients (1.14 vs. 0.17, p = 0.003). Surprisingly, in the RT
verlapping region the “a” determinant was not signiﬁcantly
ifferent in terms of frequencies of aa substitutions between
roups I and II (2.22 vs. 0.49, p = 0.073). When considering
he region of RT overlapping the C-terminal region, which
tands within the structural and functional “palm” subdomain
f the enzyme,17 the difference of aa substitutions was not
igniﬁcant between the two groups (0.82 vs. 0.52, p = 0.425).
urthermore, substitutions rtE134V, rtR138K, rtN139Q, corre-
ponding to sI126S, sG130N, sT131N, were more  frequent in
atients from group I than in patients from group II.
iscussion
he present study described the prevalence of coexistence of
nti-HBs in HBsAg-positive CHB patients infected with geno-
ype C HBV and analyzed the clinical and virological features,
ncluding aa substitutions in S gene and the overlapping
T regions. The presence of both HBsAg and anti-HBs was
ocumented in 3.0% of 1194 CHB patients, which was sim-
lar to several previous reports,12,17–20 but lower compared
o others.4,21 The prevalence diversity might be explained
y differences in demographic, ethnic, geographical diver-
ion, and diagnosis criteria. In this study, only an anti-HBs
iter > 10 mIU/mL was considered positive according to the
hinese consensus criteria.22Genotypes B and C are the most common HBV genotypes
n China, accounting for approximately 95% of HBV-infected
atients.23 Previous reports indicated that HBV genotype
 takes more  aggressive clinical course than genotype2.22 0.49 0.073
0.82 0.52 0.425
B.7,24 In addition, some studies suggested that concomi-
tant HBsAg/anti-HBs is associated with more  advanced
liver diseases, such as ﬁbrosis, cirrhosis, and hepatocellu-
lar carcinoma.21,25,26 Therefore, it is necessary to explore the
mechanism underlying the coexistence of HBsAg and anti-HBs
in genotype C CHB patients.
The mechanism underlying the simultaneous HBsAg/anti-
HBs positivity is still unknown, but one explanation might
be the selection of HBsAg immune escape variants. Sev-
eral studies reported that, for the MHR, especially for the
“a” determinant region, genetic variability in patients carry-
ing concurrent HBsAg/anti-HBs is much higher than that in
patients carrying HBsAg only.4,16,18,19,27 It has been reported
that the accumulation of aa substitutions in and around
the “a” determinant region may change the conformational
structure and immunogenicity of HBsAg and T-cell epitope
structure, leading to escape from recognition by the host
immune system.13,14 This hypothesis is strengthened by the
results of our study.
In the present study, a signiﬁcantly higher aa variability
was also observed within the MHR and the “a” determi-
nant region of HBV from HBsAg+/anti-HBs+ patients than
from controls, which is in line with previous reports.4,16,18,19,27
Whether and how these mutations affect the immunogenic-
ity of HBsAg, either alone or in combination, still needs much
more in-depth studies. However, regarding the speciﬁc aa
substitutions, mutations sI126S/T, sQ129R, sG130N, sF134I,
and sG145R found in this study were associated with alter-
ation of HBsAg antigenicity, as reported previously.4,16,18,19,27
Interestingly, the most frequent substitution sG145R reported
in previous studies was only found in one patient from group
I.4,19 This result is similar to several previous reports from
China.16,18,27 Diversities in genotypes may be an important
reason for the preferred mutations in the “a” determinant. All
patients enrolled in this study and most of those enrolled in
other studies from China were infected with genotype C HBV,
in contrast with genotypes A and D HBV prevalent in Europe
and the US.
In this study, we  also observed signiﬁcantly higher aa
variability within the RT region of HBV from group I than
from group II. Furthermore, we speciﬁcally observed signiﬁ-
cantly higher aa variability in the RT region overlapping the
MHR  region of HBsAg. However, in the RT region overlap-
ping the C terminal region of HBsAg, which is associated
with the emergence of viral resistance, there was no signif-
icant difference in the percentage of aa substitutions between
group I and group II. This result is in line with one report,16
but contradicts another study.19 Although the virological and
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clinical implications of our ﬁndings remain unknown, some
mutations in RT region have already been conﬁrmed to be
associated with speciﬁc clinical outcomes previously. Muta-
tion rtM204V, observed in one patient in our study, was
previously found to partially lead to the production and intra-
cellular retention of truncated HBsAg forms.28 In addition,
previous study has demonstrated that mutations rtL180M
and rtM204V confer Lamivudine resistance.29 Furthermore,
we  observed that the substitution rtS78T, which was found
in group I, was previously found to decrease RT binding afﬁn-
ity of adefovir and potentially contributes by itself to adefovir
resistance.30 Besides, mutation rtS78T, corresponding to a
stop-codon at the HBsAg-position 69, might potentially affect
HBV pathogenicity and oncogenic potential.31 Therefore, fur-
ther studies deserve careful follow-up of these patients once
antiviral treatments are introduced.
Notably, though most of previous reports supported the
relationship of the HBsAg sequence variations and the con-
current HBsAg/anti-HBs serological proﬁle, another study
objected. In that study, similar aa variability was found in
the HBsAg sequences derived from patients with and with-
out anti-HBs.12 They thought the exposure of patients to
HBV infection of different subtypes might be a possible
explanation.12
In summary, our study has shown the prevalence of anti-
HBs in HBsAg-positive CHB patients infected with genotype C
HBV. We  observed a higher aa variability within the N-terminal
region and the MHR, especially the “a” determinant region,
and within RT for regions overlapping the MHR in patients
with concurrent HBsAg/anti-HBs serological proﬁle. Addi-
tional research on these genetic mutants is needed to clarify
their biological signiﬁcance for viral persistence. Further stud-
ies are needed to determine whether these simultaneous HBV
mutants might positively inﬂuence the clinical course and
alter nucleos(t)ide analogs efﬁcacy.
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